138.02
price down icon6.35%   -9.36
after-market Dopo l'orario di chiusura: 138.00 -0.02 -0.01%
loading
Precedente Chiudi:
$147.38
Aprire:
$140
Volume 24 ore:
3.01M
Relative Volume:
3.29
Capitalizzazione di mercato:
$13.69B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
46.79
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
-2.44%
1M Prestazione:
-1.60%
6M Prestazione:
+28.70%
1 anno Prestazione:
+18.79%
Intervallo 1D:
Value
$133.61
$144.30
Intervallo di 1 settimana:
Value
$133.61
$149.98
Portata 52W:
Value
$84.23
$154.61

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,800
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
138.02 14.62B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
143.94 64.44B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.77 44.53B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.05 40.61B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.23 22.69B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
455.32 18.78B 3.08B 1.24B 1.07B 25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-21 Iniziato Citigroup Buy
2025-07-21 Iniziato Truist Buy
2025-07-10 Iniziato Goldman Buy
2025-04-15 Aggiornamento Needham Hold → Buy
2025-04-14 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Iniziato Deutsche Bank Hold
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
09:45 AM

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating - MarketScreener

09:45 AM
pulisher
07:51 AM

Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating - MarketScreener

07:51 AM
pulisher
07:02 AM

Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com

07:02 AM
pulisher
05:55 AM

Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherStop Loss & AI Driven Price Forecasts - newser.com

05:55 AM
pulisher
04:09 AM

What data driven models say about Neurocrine Biosciences Inc.’s futureJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - newser.com

04:09 AM
pulisher
01:11 AM

Is it time to cut losses on Neurocrine Biosciences Inc.July 2025 Highlights & Consistent Growth Stock Picks - newser.com

01:11 AM
pulisher
Oct 28, 2025

Neurocrine Biosciences Q3 2025 Earnings Call Transcript - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Profit Report & Daily Market Momentum Tracking - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine: Q3 Earnings Snapshot - Stamford Advocate

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences Tops Q3 Estimates With Growing Sales - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q3 Revenue $794.9M, vs. FactSet Est of $746.8M - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q3 Adjusted EPS $2.17 per Share, vs. FactSet Est of $2.07 - MarketScreener

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences shares rise as Q3 earnings, revenue beat expectations - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PR Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Can Neurocrine Biosciences Inc. stock sustain revenue growthQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Can Neurocrine Biosciences Inc. stock hit analyst price targetsWeekly Gains Report & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Trend Recap: How rising interest rates impact Neurocrine Biosciences Inc. stockWeekly Risk Summary & Fast Entry and Exit Trade Plans - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Short interest data insights for Neurocrine Biosciences Inc.Portfolio Risk Report & AI Driven Stock Movement Reports - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levelsMarket Rally & Risk Controlled Stock Pick Alerts - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

How rising interest rates impact Neurocrine Biosciences Inc. stock2025 Institutional Moves & Consistent Growth Equity Picks - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

What moving averages say about Neurocrine Biosciences Inc.Insider Selling & Low Risk High Win Rate Stock Picks - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

Neurocrine Biosciences (NBIX): Fresh INGREZZA Study Data Renews Focus on Valuation - simplywall.st

Oct 26, 2025
pulisher
Oct 26, 2025

Neurocrine Biosciences Experiences Revision in Its Stock Evaluation Amid Strong Market Performance - Markets Mojo

Oct 26, 2025

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$10.27
price down icon 0.19%
$22.59
price up icon 2.12%
drug_manufacturers_specialty_generic RDY
$13.41
price down icon 8.15%
$46.63
price down icon 1.04%
$455.32
price up icon 9.63%
Capitalizzazione:     |  Volume (24 ore):